
Egetis Therapeutics AB (publ)
SSE:EGTX.ST
Overview | Financials
Company Name | Egetis Therapeutics AB (publ) |
Symbol | EGTX.ST |
Currency | SEK |
Price | 6.07 |
Market Cap | 1,775,905,970 |
Dividend Yield | 0% |
52-week-range | 3.8 - 9.2 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Nicklas Westerholm |
Website | https://www.egetis.com |
An error occurred while fetching data.
About Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD